Cytokines as therapeutic targets in skin inflammation

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 443-451

  Wittmann, Miriam ^a,b,d   McGonagle, Dennis ^a,b   Werfel, Thomas ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antimicrobial peptides; Atopic dermatitis; Keratinocytes; Microbiome; Pruritus; Psoriasis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA TOXIN; CALGRANULIN; CELL SURFACE PROTEIN; CRTH2 PROTEIN; CYTOKINE; DUPILUMAB; FILAGGRIN; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HISTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 31; INTERLEUKIN 33; INTERLEUKIN 36; INTERLEUKIN 4; PROTEIN S 100; PSORIASIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATOPIC DERMATITIS; CLINICAL TRIAL (TOPIC); CUTANEOUS PARAMETERS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ECZEMA; IMMUNOREGULATION; LYMPHOID CELL; MEDIATOR RELEASE; PERMEABILITY BARRIER; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PRURITUS; PSORIASIS; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SKIN BARRIER; SKIN DEFECT; SKIN FLORA; SKIN INJURY; SKIN PH; STAPHYLOCOCCUS EPIDERMIDIS; TH17 CELL; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CYTOLOGY; DERMATITIS, ATOPIC; HUMAN; IMMUNOLOGY; INFLAMMATION; INJURIES; KERATINOCYTE; PATHOLOGY; SKIN; TIGHT JUNCTION;

CYTOKINES; DERMATITIS, ATOPIC; HUMANS; INFLAMMATION; KERATINOCYTES; PRURITUS; PSORIASIS; SKIN; TIGHT JUNCTIONS;

EID: 84908049223     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.008     Document Type: Short Survey

References (100)

1. Reich K., Mrowietz U., Karakasili E., Zschocke I. Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Arch Dermatol Res 2014.
2. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012, 67:1475-1482.
3. Novak N., Simon D. Atopic dermatitis - from new pathophysiologic insights to individualized therapy. Allergy 2011, 66:830-839.
4. Ainali C., Valeyev N., Perera G., Williams A., Gudjonsson J.E., Ouzounis C.A., et al. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics 2012, 13:472.
5. Eyerich K., Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013, 68:974-982.
6. Kamsteeg M., Jansen P.A., van Vlijmen-Willems I.M., van Erp P.E., Rodijk-Olthuis D., van der Valk P.G., et al. Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Br J Dermatol 2010, 162:568-578.
7. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J., Lane M.E., Moustafa M., et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129:1892-1908.
8. McAleer M.A., Irvine A.D. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol 2013, 131:280-291.
9. Weidinger S., Illig T., Baurecht H., Irvine A.D., Rodriguez E., Diaz-Lacava A., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006, 118:214-219.
10. Wittmann M., Kingsbury S.R., McDermott M.F. Is caspase 1 central to activation of interleukin-1?. Joint Bone Spine: revue du rhumatisme 2011, 78:327-330.
11. Elias P.M., Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol 2009, 9:437-446.
12. Howell M.D., Kim B.E., Gao P., Grant A.V., Boguniewicz M., DeBenedetto A., et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009, 124:R7-R12.
13. Hanel K.H., Cornelissen C., Luscher B., Baron J.M. Cytokines and the skin barrier. Int J Mol Sci 2013, 14:6720-6745.
14. Kamsteeg M., Bergers M., de Boer R., Zeeuwen P.L., Hato S.V., Schalkwijk J., et al. Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent. Am J Pathol 2011, 178:2091-2099.
15. Hoste E., Kemperman P., Devos M., Denecker G., Kezic S., Yau N., et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol 2011, 131:2233-2241.
16. Seltmann J., Roessner L., von Hesler F.-W., Wittmann M., Werfel T. IL-33 impacts on the skin barrier by downregulting the expression of filaggrin. J Allergy Clin Immunol 2014, (under revision).
17. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002, 3:673-680.
18. Sabat R., Ouyang W., Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014, 13:21-38.
19. Kim B.E., Howell M.D., Guttman-Yassky E., Gilleaudeau P.M., Cardinale I.R., Boguniewicz M., et al. TNF-alpha downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-alpha antagonists to improve skin barrier. J Invest Dermatol 2011, 131:1272-1279.
20. Cornelissen C., Marquardt Y., Czaja K., Wenzel J., Frank J., Luscher-Firzlaff J., et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012, 129. 426-33, 33 e1-8.
21. Boniface K., Diveu C., Morel F., Pedretti N., Froger J., Ravon E., et al. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 2007, 178:4615-4622.
22. Sandilands A., Sutherland C., Irvine A.D., McLean W.H. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci 2009, 122:1285-1294.
23. De Benedetto A., Kubo A., Beck L.A. Skin barrier disruption: a requirement for allergen sensitization?. J Invest Dermatol 2012, 132:949-963.
24. Harder J., Schroder J.M., Glaser R. The skin surface as antimicrobial barrier: present concepts and future outlooks. Exp Dermatol 2013, 22:1-5.
25. de Koning H.D., Kamsteeg M., Rodijk-Olthuis D., van Vlijmen-Willems I.M., van Erp P.E., Schalkwijk J., et al. Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J Invest Dermatol 2011, 131:263-266.
26. De Y., Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000, 192:1069-1074.
27. Kopfnagel V., Harder J., Werfel T. Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions. Curr Opin Allergy Clin Immunol 2013, 13:531-536.
28. Gallo R.L., Hooper L.V. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012, 12:503-516.
29. Kuo I.H., Yoshida T., De Benedetto A., Beck L.A. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 2013, 131:266-278.
30. Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007, 13:975-980.
31. Johnson-Huang L.M., Lowes M.A., Krueger J.G. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Models Mech 2012, 5:423-433.
32. Allen H.B., Vaze N.D., Choi C., Hailu T., Tulbert B.H., Cusack C.A., et al. The presence and impact of biofilm-producing Staphylococci in atopic dermatitis. JAMA Dermatol 2014, 150:260-265.
33. Kasraie S., Niebuhr M., Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 2010, 65:712-721.
34. Niebuhr M., Mamerow D., Heratizadeh A., Satzger I., Werfel T. Staphylococcal alpha-toxin induces a higher T cell proliferation and interleukin-31 in atopic dermatitis. Int Arch Allergy Immunol 2011, 156:412-415.
35. Breuer K., Wittmann M., Kempe K., Kapp A., Mai U., Dittrich-Breiholz O., et al. Alpha-toxin is produced by skin colonizing Staphylococcus aureus and induces a T helper type 1 response in atopic dermatitis. Clin Exp Allergy 2005, 35:1088-1095.
36. Werfel T., Wittmann M. Regulatory role of T lymphocytes in atopic dermatitis. Chem Immunol Allergy 2008, 94:101-111.
37. Brauweiler A.M., Goleva E., Leung D.Y. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 2014.
38. Alase A., Seltmann J., Werfel T., Wittmann M. Interleukin-33 modulates the expression of human beta-defensin 2 in human primary keratinocytes and may influence the susceptibility to bacterial superinfection in acute atopic dermatitis. Br J Dermatol 2012, 167:1386-1389.
39. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003, 171:3262-3269.
40. Wolk K., Warszawska K., Hoeflich C., Witte E., Schneider-Burrus S., Witte K., et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 2011, 186:1228-1239.
41. Gallo R.L., Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol 2011, 131:1974-1980.
42. Niebuhr M., Baumert K., Werfel T. TLR-2-mediated cytokine and chemokine secretion in human keratinocytes. Exp Dermatol 2010, 19:873-877.
43. Niebuhr M., Lutat C., Sigel S., Werfel T. Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. Allergy 2009, 64:1580-1587.
44. Naik S., Bouladoux N., Wilhelm C., Molloy M.J., Salcedo R., Kastenmuller W., et al. Compartmentalized control of skin immunity by resident commensals. Science 2012, 337:1115-1119.
45. Zeeuwen P.L., Boekhorst J., van den Bogaard E.H., de Koning H.D., van de Kerkhof P.M., Saulnier D.M., et al. Microbiome dynamics of human epidermis following skin barrier disruption. Genome Biol 2012, 13:R101.
46. Findley K., Oh J., Yang J., Conlan S., Deming C., Meyer J.A., et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 2013, 498:367-370.
47. Grice E.A., Kong H.H., Conlan S., Deming C.B., Davis J., Young A.C., et al. Topographical and temporal diversity of the human skin microbiome. Science 2009, 324:1190-1192.
48. Tomic-Canic M., Perez-Perez G.I., Blumenberg M. Cutaneous microbiome studies in the times of affordable sequencing. J Dermatol Sci 2014, 75:82-87.
49. Kong H.H., Oh J., Deming C., Conlan S., Grice E.A., Beatson M.A., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012, 22:850-859.
50. Di Meglio P., Duarte J.H., Ahlfors H., Owens N.D., Li Y., Villanova F., et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 2014, 40:989-1001.
51. van den Bogaard E.H., Bergboer J.G., Vonk-Bergers M., van Vlijmen-Willems I.M., Hato S.V., van der Valk P.G., et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 2013, 123:917-927.
52. Proksch E., Brandner J.M., Jensen J.M. The skin: an indispensable barrier. Exp Dermatol 2008, 17:1063-1072.
53. Chalmers J.R., Simpson E.L., Chen Y.Y., Cork M.J., Brown S.J., Thomas K.S., et al. Feasibility study of barrier enhancement for eczema prevention (BEEP). Br J Dermatol 2014, 170.
54. Kerkhoff C., Voss A., Scholzen T.E., Averill M.M., Zanker K.S., Bornfeldt K.E. Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol 2012, 21:822-826.
55. Glaser R., Meyer-Hoffert U., Harder J., Cordes J., Wittersheim M., Kobliakova J., et al. The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol 2009, 129:641-649.
56. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388.
57. Wang D., Eiz-Vesper B., Zeitvogel J., Dressel R., Werfel T., Wittmann M. Human keratinocytes release high levels of inducible heat shock protein 70 that enhances peptide uptake. Exp Dermatol 2011, 20:637-641.
58. Figueiredo C., Wittmann M., Wang D., Dressel R., Seltsam A., Blasczyk R., et al. Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells. Blood 2009, 113:3008-3016.
59. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009, 206:1983-1994.
60. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
61. Jordan C.T., Cao L., Roberson E.D., Pierson K.C., Yang C.F., Joyce C.E., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012, 90:784-795.
62. Nograles K.E., Brasington R.D., Bowcock A.M. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009, 5:83-91.
63. Hebert H.L., Ali F.R., Bowes J., Griffiths C.E., Barton A., Warren R.B. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2012, 166:474-482.
64. Bergboer J.G., Zeeuwen P.L., Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012, 132:2320-2321.
65. Lloyd C.M. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol 2010, 22:800-806.
66. Dickel H., Gambichler T., Kamphowe J., Altmeyer P., Skrygan M. Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-alpha and IL-8/CXCL8 mRNA: new insights into the involvement of 'alarmins'. Contact Dermat 2010, 63:215-222.
67. Angelova-Fischer I., Fernandez I.M., Donnadieu M.H., Bulfone-Paus S., Zillikens D., Fischer T.W., et al. Injury to the stratum corneum induces in vivo expression of human thymic stromal lymphopoietin in the epidermis. J Invest Dermatol 2010, 130:2505-2507.
68. Oyoshi M.K., Larson R.P., Ziegler S.F., Geha R.S. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin Immunol 2010, 126:976-84, 84 e1-5.
69. Kurahashi R., Hatano Y., Katagiri K. IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J Invest Dermatol 2008, 128:1329-1331.
70. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011, 12:21-27.
71. Mjosberg J.M., Trifari S., Crellin N.K., Peters C.P., van Drunen C.M., Piet B., et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011, 12:1055-1062.
72. Kakkar R., Hei H., Dobner S., Lee R.T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012, 287:6941-6948.
73. Rossbach K., Wendorff S., Sander K., Stark H., Gutzmer R., Werfel T., et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009, 18:57-63.
74. Gschwandtner M., Mildner M., Mlitz V., Gruber F., Eckhart L., Werfel T., et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013, 68:37-47.
75. Steinhoff M., Bienenstock J., Schmelz M., Maurer M., Wei E., Biro T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006, 126:1705-1718.
76. Cevikbas F., Wang X., Akiyama T., Kempkes C., Savinko T., Antal A., et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 2014, 133:448-460.
77. Neis M.M., Peters B., Dreuw A., Wenzel J., Bieber T., Mauch C., et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006, 118:930-937.
78. Bilsborough J., Leung D.Y., Maurer M., Howell M., Boguniewicz M., Yao L., et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006, 117:418-425.
79. Nobbe S., Dziunycz P., Muhleisen B., Bilsborough J., Dillon S.R., French L.E., et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Dermat Venereol 2012, 92:24-28.
80. Sonkoly E., Muller A., Lauerma A.I., Pivarcsi A., Soto H., Kemeny L., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411-417.
81. Dillon S.R., Sprecher C., Hammond A., Bilsborough J., Rosenfeld-Franklin M., Presnell S.R., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004, 5:752-760.
82. Heise R., Neis M.M., Marquardt Y., Joussen S., Heinrich P.C., Merk H.F., et al. IL-31 receptor alpha expression in epidermal keratinocytes is modulated by cell differentiation and interferon gamma. J Invest Dermatol 2009, 129:240-243.
83. Kasraie S., Niebuhr M., Baumert K., Werfel T. Functional effects of interleukin 31 in human primary keratinocytes. Allergy 2011, 66:845-852.
84. Venereau E., Diveu C., Grimaud L., Ravon E., Froger J., Preisser L., et al. Definition and characterization of an inhibitor for interleukin-31. J Biol Chem 2010, 285:14955-14963.
85. Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11:1014-1022.
86. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
87. Teng X., Hu Z., Wei X., Wang Z., Guan T., Liu N., et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol 2014, 192:1815-1823.
88. van de Veerdonk F.L., Stoeckman A.K., Wu G., Boeckermann A.N., Azam T., Netea M.G., et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 2012, 109:3001-3005.
89. Villanova F., Di Meglio P., Nestle F.O. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheumatic Dis 2013, 72(Suppl. 2):104-110.
90. Chang H.Y., Chi J.T., Dudoit S., Bondre C., van de Rijn M., Botstein D., et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002, 99:12877-12882.
91. Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgE in the development of atopic dermatitis. J Invest Dermatol 2009, 129:1878-1891.
92. Johnson-Huang L.M., Suarez-Farinas M., Pierson K.C., Fuentes-Duculan J., Cueto I., Lentini T., et al. A single intradermal injection of IFN-gamma induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol 2012, 132:1177-1187.
93. Carrier Y., Ma H.L., Ramon H.E., Napierata L., Small C., O'Toole M., et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol 2011, 131:2428-2437.
94. Johnston A., Xing X., Guzman A.M., Riblett M., Loyd C.M., Ward N.L., et al. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011, 186:2613-2622.
95. Muhr P., Zeitvogel J., Heitland I., Werfel T., Wittmann M. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol 2011, 165:189-193.
96. Towne J.E., Renshaw B.R., Douangpanya J., Lipsky B.P., Shen M., Gabel C.A., et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011, 286:42594-42602.
97. Marrakchi S., Guigue P., Renshaw B.R., Puel A., Pei X.Y., Fraitag S., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011, 365:620-628.
98. Onoufriadis A., Simpson M.A., Pink A.E., Di Meglio P., Smith C.H., Pullabhatla V., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89:432-437.
99. Wolk K., Haugen H.S., Xu W., Witte E., Waggie K., Anderson M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 2009, 87:523-536.
100. Martin S.F. Contact dermatitis: from pathomechanisms to immunotoxicology. Exp Dermatol 2012, 21:382-389.